<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karaflou, M.</style></author><author><style face="normal" font="default" size="100%">Kaparos, G.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.</style></author><author><style face="normal" font="default" size="100%">Creatsa, M.</style></author><author><style face="normal" font="default" size="100%">Christodoulakos, G.</style></author><author><style face="normal" font="default" size="100%">Lambrinoudaki, I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Estrogen plus progestin treatment: Effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Fertility and Sterility</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">cyt-c</style></keyword><keyword><style  face="normal" font="default" size="100%">drospirenone</style></keyword><keyword><style  face="normal" font="default" size="100%">Estrogen</style></keyword><keyword><style  face="normal" font="default" size="100%">Fas</style></keyword><keyword><style  face="normal" font="default" size="100%">FasL</style></keyword><keyword><style  face="normal" font="default" size="100%">hormone therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">norethisterone</style></keyword><keyword><style  face="normal" font="default" size="100%">progestin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">94</style></volume><pages><style face="normal" font="default" size="100%">2399 - 2401</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">One hundred healthy postmenopausal women were randomly assigned to receive 17β-E2 1 mg/drospirenone 2 mg or 17β-E2 1 mg/norethisterone acetate 0.5 mg for 6 months, and circulating soluble Fas, soluble Fas ligand, and cytochrome c were measured at baseline and at 6 months in 87 women who completed the study. Although cytochrome c levels were undetectable, circulating soluble Fas/soluble Fas ligand ratio decreased in both groups, suggesting a decrease in ligand-mediated apoptosis. Copyright © 2010 American Society for Reproductive Medicine, Published by Elsevier Inc.</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue></record></records></xml>